Enhancement of Radiation Dose to the Nucleus by Vesicular Internalization of Iodine-125-Labeled A33 Monoclonal Antibody

Journal of Nuclear Medicine

Volumn 37, Issue 6, 1996, Pages 1052-1057

  Daghighian, Farhad ^a   Barendswaard, Els ^b   Welt, Sydney ^b   Humm, John ^b   Scott, Andrew ^b   Willingham, Mark C ^b   McGuffie, Eileen ^b   Old, Lloyd J ^b   Larson, Steven M ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

Auger electrons, cell level dosimetry; Monoclonal antibody; Vesicular internalization

Indexed keywords

MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ARTICLE; CELL CULTURE; CELL NUCLEUS; CELL VACUOLE; COLON TUMOR; CYTOTOXICITY; HUMAN; IMMUNOLOGY; METABOLISM; RADIATION DOSE; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; ULTRASTRUCTURE;

ANTIBODIES, MONOCLONAL; CELL NUCLEUS; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IODINE RADIOISOTOPES; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; TUMOR CELLS, CULTURED; VACUOLES;

EID: 0030160773     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jain RK, Baxter MJ. Mechanism of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial fluid pressure. Cancer Res 1988;48:7022-7032.
2. Ong GL, Mattes MJ. Penetration and binding of antibodies in experimental human solid tumors grown in mice. Cancer Res 1989;49:4264-4273.
3. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-5153.
4. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990;9:253-266.
5. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986;27:1490-1497.
6. Mausner LF, Srivastava SC. Selection of radionuclides for radioimmunotherapy. Med Phys 1993;20:503-509.
7. 131I-labeled monoclonal antibodies administered to man. Int J Radiat Appl Instrum 1989;16:153-158.
8. 131I-Lym-1 as a model. Cancer 1994;73:1038-1048.
9. Barendswaard EC, Welt S, Divgi CR, Garin-Chesa P, Williams C, Old LJ. Anti-colon cancer monoclonal antibody 100-310: in vitro studies and in vivo localization [Abstract]. Proc American Assoc for Cancer Res 1992;33:345.
10. Welt S, Divgi CR, Real FX, et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase 1 study of monoclonal antibody A33. J Clin Oncol 1990;8:1894-1906.
11. Howell RW. Radiation spectra for Auger-electron emitting radionuclides: report no. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1992;19:1371-1383.
12. Kassis AI, Howell RW, Sastry KSR, Adelstein SJ. Positional effects of Auger decays in mammalian cells in culture. In: Baverstock KF, Charlton DE, eds. DNA Damage by Auger Emitters. London, Taylor and Francis;1988;1-14.
13. 3H: nuclear versus cytoplasmic radiation effects in murine L1210 leukemia. Int J Radiat Biol 1975;28:225-241.
14. Hofer KG. Radiation biology and potential therapeutic applications of radionuclides. Bull Cancer (Paris) 1980;67:343-353.
15. Howell RW, Narra VR, Sastry KSR, Rao DV, eds. Biological aspects of Auger processes. American Institute of Physics, Woodbury, N.Y. 1992.
16. Humm JL, Howell RW, Rao DV. Dosimetry for Auger electron emitters: report No. 3 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1994;21:1901-1915.
17. Goddu SM, Rao DV, Howell RW. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on the type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med 1994;35:521-530.
18. Welt S, Divgi CR, Kemeny N, et al. Phase I/II study of iodine-131 : labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994;12:1561-1571.
19. Willingham MC, Pastan I. Morphologic methods in the study of endocytosis in cultured cells. In: Pastan I, Willingham MC, eds. Endocytosis. New York: Plenum Press; 1985:281-320.
20. 125IUdR)by resistant cancer. Br J Radiol 1991;64:37-44.
21. Mariani G, Cei A, Collecchi P, et al. Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2′-deoxyuridine following intratumoral injection in patients with colorectal cancer. J .Nucl Med 1993;34:1175-1183.
22. 125I-IUdR in the treatment of colorectal cancer metastatic to liver. J Nucl Med 1996; 37:(suppl):29S-32S.
23. 125I-5′-iododeoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med 1996;37:(suppl):25S-29S.
24. 35S: theory and application to a cellular model. Radiat Res 1980;84:407-425.
25. 125I-labeled 9.2.27 monoclonal antibody. Cancer Res 1985;45: 5080-5087.
26. 125I-labeled monoclonal antibody 17-1-A in human cancer cells. Cancer Res 1989;49:2952-2958.
27. Cole A. Absorption of 20-eV to 50,000-eV electron beams in air and plastic. Radiat Res 1969;38:7-33.